InstaDoc CAIHL draft report

InstaDoc: CAIHL reassessment

September 8, 2026. Published AI-assisted draft.

InstaDoc’s current homepage separates informational AI results from optional licensed-clinician care. It describes patient choices over escalation and onward sharing. Earlier pricing, prescribing, and legal findings remain historical because the detailed policies could not be refreshed.

Scope and agency posture

Patient-initiated AI intake with optional affiliated clinical care. Preserve the July 30 baseline of 82 and founder-profile submission provenance.

Posture: Potentially agency-expanding, with clinical-governance, verification, and disclosure contradictions.

Axis: 82/100, retained provisionally. No numerical recalibration was performed.

Sources and documented findings

• The current homepage now leads with informational results followed, where appropriate, by independent licensed-clinician care. It says patients choose paid care and waiting time, approve a prescription before payment, and choose whether to send intake onward. It describes no sale or AI training, while leaving storage duration as operationally necessary. These are published promises, not observed controls.

• Direct retrieval of the existing terms and privacy page failed. One targeted official-domain search returned the homepage but did not recover those policies. The July board-certified-verification clause, inconsistent prices and pending e-prescribing details therefore remain historical findings, not newly confirmed defects.

Patient authority

Inference from the documented workflow: Patients still define the initial problem and choose clinical escalation. The current homepage makes prepayment review and waiting-time choice more explicit. Whether patients can revise or contest the free AI assessment remains unresolved.

Critical capacity

Editorial assessment: Symptom reflection and possible next steps may help patients prepare questions. The claim to use clinical references does not establish visible citations, calibrated uncertainty or validation for a particular answer.

Informed control

Editorial assessment: Current front-page scope is clearer than the prior urgent-care framing, but anonymity and no-training promises cannot be reconciled against inaccessible policy text in this pass. Clinical and software rights should remain distinct.

Assessment and limits

Update the current description and date the older contradictions accurately. Do not continue saying that today's homepage markets urgent care when the retrieved page instead distinguishes information and licensed care. Inaccessible policies prevent resolving the remaining conditions.

Confidence: Low to medium, current homepage only.

Remaining uncertainty: Legal verification requirements, detailed data path, state coverage, final prices, e-prescribing readiness and output correction could not be refreshed.

Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.

Review provenance

• Reviewer/model: OpenAI Codex / GPT-6.
• Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
• Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
• Earlier review: 2026-07-30. Historical assessment. Earlier claims are not automatically reverified by this publication.

Disclosures

Brought to HugoScore through a founder-profile screenshot. not an endorsement. A screenshot of founder Jon Pangia's public LinkedIn profile brought InstaDoc to HugoScore's attention on 2026-07-30. The screenshot was treated as a lead, not evidence for product claims. Publishing this draft does not endorse the founder, vendor, medical group, or service.